IMTX Stock - Immatics N.V.
Unlock GoAI Insights for IMTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $155.84M | $54.00M | $172.83M | $34.76M | $31.25M |
| Gross Profit | $155.84M | $-64,666,000 | $66.05M | $-52,811,000 | $-35,832,000 |
| Gross Margin | 100.0% | -119.8% | 38.2% | -151.9% | -114.7% |
| Operating Income | $-38,615,000 | $-101,725,000 | $29.95M | $-86,294,000 | $-69,715,000 |
| Net Income | $15.22M | $-96,994,000 | $37.51M | $-95,061,000 | $-229,348,000 |
| Net Margin | 9.8% | -179.6% | 21.7% | -273.5% | -733.8% |
| EPS | $0.14 | $-1.20 | $0.55 | $-1.51 | $-4.78 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 18th 2025 | Guggenheim | Initiation | Buy | $16 |
| May 28th 2025 | Deutsche Bank | Initiation | Buy | $10 |
| October 7th 2024 | Piper Sandler | Initiation | Overweight | $19 |
| November 2nd 2023 | Cantor Fitzgerald | Initiation | Overweight | - |
| March 31st 2023 | Mizuho | Initiation | Buy | $12 |
| March 24th 2023 | Bryan Garnier | Initiation | Buy | $16 |
Earnings History & Surprises
IMTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.48 | — | — | — |
Q4 2025 | Nov 17, 2025 | $-0.44 | $-0.49 | -11.5% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.38 | $-0.66 | -73.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.39 | $-0.35 | +10.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.33 | $0.48 | +245.5% | ✓ BEAT |
Q4 2024 | Nov 18, 2024 | $-0.27 | $-0.12 | +55.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.35 | $-0.18 | +48.6% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.74 | $-0.04 | +94.6% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.41 | $-0.32 | +22.0% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 17, 2023 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q2 2023 | May 16, 2023 | $-0.35 | $-0.28 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 21, 2023 | $0.17 | $-0.23 | -235.3% | ✗ MISS |
Q4 2022 | Nov 17, 2022 | $-0.31 | $-0.32 | -3.2% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.13 | $-0.23 | -276.9% | ✗ MISS |
Q2 2022 | Jun 2, 2022 | $1.76 | $1.35 | -23.3% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $1.94 | $-0.30 | -115.5% | ✗ MISS |
Q4 2021 | Nov 16, 2021 | $-0.31 | $-0.51 | -64.5% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.38 | $-0.46 | -21.1% | ✗ MISS |
Q2 2021 | May 18, 2021 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Latest News
Immatics Unveils IMA203CD8 Phase 1a Findings Demonstrating Durable Responses And Tumor-Agnostic Potential In PRAME-Expressing Cancers
📈 PositiveImmatics shares are trading lower after the company announced a $125 million offering of 12.5 million shares at $10 per share.
📉 NegativeImmatics To Raise $125M Through Sale of 12.5M Shares at $10 Each
➖ NeutralChardan Capital Maintains Buy on Immatics, Maintains $25 Price Target
📈 PositiveMizuho Maintains Outperform on Immatics, Raises Price Target to $23
📈 PositiveImmatics shares are trading higher after Guggenheim maintained a Buy rating and raised its price target on the stock from $16 to $19.
📈 PositiveGuggenheim Maintains Buy on Immatics, Raises Price Target to $19
📈 PositiveImmatics Q3 Sales $6.100M Miss $12.300M Estimate
📉 NegativeImmatics shares are trading higher after the company announced updated Phase 1a dose escalation data from both product candidates in its TCR Bispecifics pipeline
📈 PositiveImmatics Achieves Clinical Proof-Of-Concept For TCER Pipeline: IMA402 (PRAME) 30% cORR, IMA401 (MAGEA4/8) Up To 29% cORR; Initiates Phase 1b And Plans Combo In sqNSCLC
📈 PositiveImmatics Presents Updated Data From 16 Patients With Metastatic Uveal Melanoma Treated With Anzu-Cel PRAME Cell Therapy At ESMO 2025 Presidential Symposium
➖ NeutralImmatics Appoints Venkat Ramanan As CFO, Effective Immediately, Succeeding Arnd Christ
➖ NeutralGuggenheim Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $16
📈 PositiveImmatics rises on data from early stage cell therapy trial
📈 PositiveFrequently Asked Questions about IMTX
What is IMTX's current stock price?
What is the analyst price target for IMTX?
What sector is Immatics N.V. in?
What is IMTX's market cap?
Does IMTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMTX for comparison